Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Jefferson Research
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Allergan Inc Issues Q1 2013 Mixed Guidance; Issues FY 2013 Guidance Below Analysts' Estimates


Tuesday, 5 Feb 2013 09:00am EST 

Allergan Inc announced that for fiscal 2013, it expects net sales between $5,900 million and $6,200 million, non-GAAP diluted earnings per share attributable to stockholders between $4.75 and $4.83. For first quarter of 2013, it expects net sales between $1,375 million and $1,450 million and non-GAAP diluted earnings per share attributable to stockholders between $0.94 and $0.96. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $6,276 million and EPS of $4.74 for fiscal 2013; revenue of $1,487 million and EPS of $1.03 for first quarter of 2013. 

Company Quote

212.63
0.45 +0.21%
19 Dec 2014